0
Axsome Therapeutics Inc. Banner Image

Axsome Therapeutics Inc.

  • Ticker AXSM
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Axsome Therapeutics Inc. Logo Image
  • 51-200 Employees
  • Based in New York City, New York
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome’s core CNS product candidate portfolio includesMore five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), treatment resistant depression (TRD), Alzheimer’s disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.
REPORT RATINGS
4.8 / 5.0 (195)

Axsome Therapeutics Inc. reports have an aggregate usefulness score of 4.8 based on 195 reviews.

Axsome Therapeutics Inc.

Most Recent Annual Report

Axsome Therapeutics Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Axsome Therapeutics Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!